- Home
- GDEV vs KMDA Comparison
GDEV vs KMDA Comparison
Compare GDEV & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEV
- KMDA
- Stock Information
- Founded
- GDEV 2009
- KMDA 1990
- Country
- GDEV Cyprus
- KMDA Israel
- Employees
- GDEV N/A
- KMDA N/A
- Industry
- GDEV EDP Services
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- GDEV Technology
- KMDA Health Care
- Exchange
- GDEV Nasdaq
- KMDA Nasdaq
- Market Cap
- GDEV 427.5M
- KMDA 349.6M
- IPO Year
- GDEV N/A
- KMDA N/A
- Fundamental
- Price
- GDEV $18.60
- KMDA $7.16
- Analyst Decision
- GDEV Buy
- KMDA Strong Buy
- Analyst Count
- GDEV 2
- KMDA 2
- Target Price
- GDEV $70.00
- KMDA $14.50
- AVG Volume (30 Days)
- GDEV 5.0K
- KMDA 142.0K
- Earning Date
- GDEV 11-14-2024
- KMDA 03-05-2025
- Dividend Yield
- GDEV N/A
- KMDA N/A
- EPS Growth
- GDEV N/A
- KMDA 124.29
- EPS
- GDEV 2.04
- KMDA 0.27
- Revenue
- GDEV $432,534,000.00
- KMDA $158,380,000.00
- Revenue This Year
- GDEV N/A
- KMDA $15.81
- Revenue Next Year
- GDEV $9.01
- KMDA $5.79
- P/E Ratio
- GDEV $9.14
- KMDA $26.36
- Revenue Growth
- GDEV N/A
- KMDA 4.52
- 52 Week Low
- GDEV $17.47
- KMDA $4.74
- 52 Week High
- GDEV $42.76
- KMDA $8.00
- Technical
- Relative Strength Index (RSI)
- GDEV 40.40
- KMDA 70.04
- Support Level
- GDEV $17.47
- KMDA $7.00
- Resistance Level
- GDEV $19.00
- KMDA $8.00
- Average True Range (ATR)
- GDEV 0.71
- KMDA 0.31
- MACD
- GDEV 0.23
- KMDA 0.06
- Stochastic Oscillator
- GDEV 40.94
- KMDA 60.93
About GDEV GDEV Inc.
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.